Evidence map›Paper›PMID 37667525›Full record

ArticleESC heart failure2023

Effect of blood pressure index on clinical outcomes in patients with heart failure and chronic kidney disease.

Ying Yuan, Menghui Liu, Shaozhao Zhang, Yifen Lin, Yiquan Huang, Huimin Zhou, Xingfeng Xu, Xiaodong Zhuang, Xinxue Liao

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00304148 (Prospective Cohort Study of Chronic Renal Insufficiency), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00304148 active not recruitingnot on this map

Prospective Cohort Study of Chronic Renal Insufficiency

TypeobservationalSponsorUniversity of PennsylvaniaRan2003 to 2028Enrolled5,499ConditionsRenal Insufficiency, Chronic
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ying YuanDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-2706-9177
Menghui LiuDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Shaozhao ZhangDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Yifen LinDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Yiquan HuangDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Huimin ZhouDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xingfeng XuDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xiaodong ZhuangDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xinxue LiaoDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study aimed to assess the effect of blood pressure (BP) index, in terms of level and variability, on the progression of cardiovascular and renal diseases in patients with both heart failure (HF) and chronic kidney disease (CKD). METHODS AND

resultsThe study involved patients with HF and CKD from the database of the Chronic Renal Insufficiency Cohort (CRIC) study. The study endpoint includes the following: (i) primary endpoint, including cardiovascular disease (CVD) events, renal events, and all-cause death; (ii) CVD events; (iii) renal events; and (iv) all-cause death. Among 3939 participants in the CRIC study, a total of 382 patients were included. The duration of the follow-up was 6.3 ± 2.7 years, the age was 60.2 ± 8.9 years, and 57.6% were male. BP index included 20 indicators in relation to BP level and variability, 4 of which were analysed including baseline systolic BP (SBP), standard deviation of SBP, coefficient of variation of diastolic BP (DBP CV), and average real variability of pulse pressure. In the Cox regression analysis after adjustment, baseline SBP was significant for the risk of primary endpoint [hazard ratio (HR) 1.22, 95% confidence interval (CI) 1.03-1.44, P = 0.02] and renal events (HR 1.54, 95% CI 1.22-1.95, P < 0.001), and DBP CV was significant for the risk of primary endpoint (HR 1.03, 95% CI 1.01-1.06, P = 0.02) and CVD events (HR 1.04, 95% CI 1.02-1.07, P < 0.01). The result of the forest plot depicted that baseline SBP had a linear association with the risk of CVD and renal events (P = 0.04 and 0.001, respectively) and DBP CV with CVD events (P = 0.02). As the restricted cubic spline models displayed, DBP CV featured a J- or L-curved association with the primary endpoint, renal events, and all-cause death (P for nonlinearity = 0.01, <0.001, and 0.01, respectively).

conclusionsThe baseline SBP and DBP CV may remain significant for clinical outcomes in patients with both HF and CKD. The increase in baseline SBP is associated with a higher risk of primary endpoint, CVD events, and renal events, and the increase in DBP CV with a higher risk of CVD events. Concerning nonlinear association, DBP CV features a J- or L-curved relationship with the primary endpoint, renal events, and all-cause death, with a higher risk at both low and high values.

trial registrationhttps://www. CLINICALTRIALS: gov; unique identifier: NCT00304148.

Indexed as

Cardiovascular DiseasesHeart FailureRenal Insufficiency, ChronicAgedBlood PressureFemaleHumansMaleMiddle AgedRisk FactorsBlood pressureBlood pressure variabilityChronic kidney diseaseHeart failureThe CRIC study

Identifiers

PMID37667525
PMCPMC10682879
OpenAlexW4386439028

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.